AI Article Synopsis
Article Abstract
By two subcutaneous or intramuscular injections of 20-methylcholanthrene (MC), 5 mg/animal in vegetal oil, followed after 74 days by 10 mg of MC emulsion, sarcomata were obtained in 63.6% of Jensen sarcoma-resistant rats (R) and in 36.8% of Jensen sarcoma-sensitive rats (S). One of the induces sarcomas, transplanted from R to R and then to S rats, presented a very high antigenicity: it strongly immunised receptive rats against the induced sarcoma and also, in a lower degree, against the Jensen sarcoma. Antigenicity was maintained up to the tenth passage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00422491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas.
Pathol Oncol Res
January 2025
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
The () gene family is of rising importance as their fusions are oncogenic, and specific target drugs are available to inhibit the chimera proteins. Pan-TRK antibody, which shows the overexpression of the genes, is a useful tool to detect tumors with or without gene alterations, due to high negative predictive value. Though it is well known that pan-TRK immunopositivity is usually not connected to fusion, the role of other possible genetic alterations is under-researched.
View Article and Find Full Text PDFPreclinical models of soft tissue sarcomas - generation and applications to enhance translational research.
Crit Rev Oncol Hematol
January 2025
Edinburgh Cancer Research, CRUK Scotland Centre, University of Edinburgh, Crewe Road South, Edinburgh EH4 2RX, UK. Electronic address:
Soft tissue sarcomas (STS) represent a large group of rare and ultra-rare tumors distinguished by unique morphological, molecular and clinical features. Patients with such rare cancers are generally underrepresented in clinical trials which has limited the introduction of new treatment options and subsequent improvement of patient outcomes. Preclinical models of STS that recapitulate the human disease can aid progress in identifying new effective treatments.
View Article and Find Full Text PDFButhionine sulfoximine acts synergistically with doxorubicin as a sensitizer molecule on different tumor cell lines.
J Toxicol Environ Health A
January 2025
Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí, Teresina-PI, Brazil.
The chemotherapeutic drug doxorubicin (DOX) has been widely used for treating solid tumors attributed to its antiproliferative effectiveness; however, its clinical use is limited due to side effects, including cardiotoxicity, myelosuppression, and drug resistance. Combining DOX with buthionine sulfoximine (BSO), a glutathione (GSH) synthesis inhibitor, showed promising results in overcoming these adverse effects, potentially reducing the required DOX dose while maintaining efficacy. The aim of the present study was to examine the effects of different concentrations of BSO and DOX, both individually and in combination, utilizing B16/F10 (murine melanoma), SNB-19 (human glioblastoma), S180 (murine sarcoma), and SVEC4-10 (murine endothelial) cell lines.
View Article and Find Full Text PDFSingle-molecule toxicogenomics: Optical genome mapping of DNA-damage in nanochannel arrays.
DNA Repair (Amst)
January 2025
School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv 6997801, Israel; Department of Biomedical Engineering, Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 6997801, Israel. Electronic address:
Quantitative genomic mapping of DNA damage may provide insights into the underlying mechanisms of damage and repair. Sequencing based approaches are bound to the limitations of PCR amplification bias and read length which hamper both the accurate quantitation of damage events and the ability to map them to structurally complex genomic regions. Optical Genome mapping in arrays of parallel nanochannels allows physical extension and genetic profiling of millions of long genomic DNA fragments, and has matured to clinical utility for characterization of complex structural aberrations in cancer genomes.
View Article and Find Full Text PDFRecommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy.
Neurol Neurochir Pol
January 2025
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!